The coagulation system in endocrine disorders: A narrative review

Internal and Emergency Medicine

Volumn 2, Issue 2, 2007, Pages 76-83

  Squizzato, A ^a   Gerdes, V E A ^b   Ageno, W ^a   Buller H R ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Bleeding; Coagulation; Growth hormone; Hypercortisolism; Hyperthyroidism; Hypothyroidism; Thrombosis

Indexed keywords

GLUCOCORTICOID; HUMAN GROWTH HORMONE;

ADDISON DISEASE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CUSHING SYNDROME; ENDOCRINE DISEASE; HOMEOSTASIS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; PHYSIOLOGY; REVIEW;

ADDISON DISEASE; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; CUSHING SYNDROME; ENDOCRINE SYSTEM DISEASES; GLUCOCORTICOIDS; HOMEOSTASIS; HUMAN GROWTH HORMONE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM;

EID: 38549145782     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-007-0026-x     Document Type: Review

References (77)

1. Orwoll ES, Orwoll RL (1987) Hematologic abnormalities in patients with endocrine and metabolic disorders. Hematol Oncol Clin North Am 1:261-279
2. Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM (2003) Estrogens, progestogens and thrombosis. J Thromb Haemost 1:1371-1380
3. Winkler UH (1996) Effects of androgens on haemostasis. Maturitas 24:147-155
4. Hartgens F, Kuipers H (2004) Effects of androgenic-anabolic steroids in athletes. Sports Med 34:513-554
5. Sowers MFR, Jannausch M, Randolph JF et al (2005) Androgens are associated with hemostatic and inflammatory factors among women at the mid-life. J Clin Endocrinol Metab 90:6064-6071
6. Hofbauer LC, Heufelder AE (1997) Coagulation disorders in thyroid diseases. Eur J Endocrinol 136:1-7
7. Marongiu F, Cauli C, Mariotti S (2004) Thyroid, hemostasis and thrombosis. J Endocrinol Invest 27:1065-1071
8. Shih CH, Chen SL, Yen CC et al (2004) Thyroid hormone receptor dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology 145:2804-2814
9. Ford HC, Carter JM (1990) Haemostasis in hypothyroidism. Postgrad Med J 66:280-284
10. Erem C, Kavgaci H, Ersoz HO et al (2003) Blood coagulation and fibrinolytic activity in hypothyroidism. Int J Clin Pract 57:78-81
11. Dalton RG, Dewar MS, Savidge GF et al (1987) Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1:1007-1009
12. Michiels JJ, Schroyens W, Berneman Z, van der Planken M (2001) Acquired von Willebrand syndrome 1 in hypothy-roidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost 7:113-115
13. Franchini M, Veneri D, Lippi G (2005) Analysis of thyroid hormone status in 131 consecutive individuals with low von Willebrand factor levels. Thromb Haemost 93:392-393
14. Franchini M, De Gironcoli M, Lippi G et al (2002) Efficacy of desmopressin as surgical prophylaxis in patients with acquired von Willebrand disease undergoing thyroid surgery. Haemophilia 8:142-144
15. Franchini M, Zugni C, Veneri D et al (2004) High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery. Haematologica 89:1346
16. Egeberg BO (1963) Influence of thyroid function on the blood clotting system. Scand J Clin Lab Invest 15:1-7
17. Simone JV, Abildgaard CF, Schulman I (1965) Blood coagulation in thyroid dysfunction. N Engl J Med 273:1057-1061
18. Nordoy A, Vikmo H, Berntsen H (1976) Haemostatic and lipid abnormalities in hypothyroidism. Scand J Haematol 16:154-160
19. Muller B, Tsakiris DA, Roth CB et al (2001) Haemostatic profile in hypothyroidism as potential risk for vascular or thrombotic disease. Eur J Clin Invest 31:131-137
20. Chadaverian R, Bruckert E, Ankri A et al (1998) Relationship between thyroid hormones and plasma D-dimer levels. Thromb Haemost 79:99-103
21. Chadaverian R, Bruckert E, Leenhardt L et al (2001) Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 86:732-737
22. Erem C, Ersoz H, Karti SS et al (2002) Blood coagulation and fibrinolysis in hyperthyroidism. J Endocrinol Invest 25:345-350
23. Marongiu F, Conti M, Mameli G et al (1988) Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. J Endocrinol Invest 11:723-725
24. Kellet HA, Sawers JSA, Boulton FE et al (1986) Problems of anticoagulation with warfarin in hyperthyroidism. Q Med J 58:43-51
25. Rogers JS II, Shane SR (1983) Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 102:444
26. Squizzato A, Gerdes VE, Brandjes DP et al (2005) Thyroid diseases and cerebrovascular disease. Stroke 36:2302-2310
27. Stam J (2005) Thrombosis of the cerebral veins and sinuses. N Engl J Med 352:1791-1798
28. Boscaro M, Barzon L, Fallo F, Sonino N (2001) Cushing's syndrome. Lancet 357:783-791
29. La Brocca A, Terzolo M, Pia A et al (1997) Recurrent thromboembolism as a hallmark of Cushing's syndrome. J Endocrinol Invest 20:211-214
30. Yoshimura S, Ago T, Kitazono T et al (2005) Cerebral sinus thrombosis in a patient with Cushing's syndrome. J Neurol Neurosurg Psychiatry 76:1182-1183
31. Sjoberg HE, Blomback M, Granberg PO (1976) Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing's syndrome. Acta Med Scand 199:95-98
32. Patrassi GM, Dal Bo Zanon R, Boscaro M et al (1985) Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thromb Haemost 54:518-520
33. Fatti LM, Bottasso B, Invitti C et al (2000) Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 23:145-150
34. Patrassi GM, Sartori MT, Viero ML et al (1992) The fibri-nolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis 3:789-793
35. Ambrosi B, Sartorio A, Pizzocaro A et al (2000) Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentalo-ma. Exp Clin Endocrinol Diabetes 108:294-298
36. Boscaro M, Sonino N, Scarda A et al (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 87:3662-3666
37. Feuillet L, Guedj E, Laksiri N et al (2004) Deep vein thrombosis after intravenous immunoglobulins associated with methylprednisolone. Thromb Haemost 92:662-665
38. Isacson S (1970) Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haematol 7:212-216
39. Ozsoylu S, Stauss HS, Diamond LK (1962) Effects of corti-costeroids on coagulation of blood. Nature 195:1214-1215
40. Jorgensen KA, Sorensen P, Freund L (1982) Effect of gluco-corticosteroids on some coagulation test. Acta Haematol 68:39-43
41. van Giezen JJ, Jansen JW (1992) Inhibition of fibrinolytic activity in vivo by dexamethasone is counterbalanced by an inhibition of platelet aggregation. Thromb Haemost 68:69-73
42. Muhlfelder TW, Niemetz J, Kang S (1982) Glucocorticoids inhibit the generation of leukocyte procoagulant (tissue factor) activity. Blood 60:1169-1172
43. Lieberman E, Heuser E, Gilchrist GS et al (1968) Thrombosis, nephrosis, and corticosteroid therapy. J Pediatr 73:320-328
44. Matusiewicz R, Stempniak M, Lebiedowski K et al (1989) The most frequent complications during long-term corti-cotherapy. Wiad Lek 42:273-277
45. Cosgriff S (1951) Thromboembolic complications associated with ACTH and cortisone therapy. JAMA 147:924-926
46. Brotman DJ, Girod JP, Posch A et al (2005) Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 118:247-252
47. Brotman DJ, Girod JP, Garcia MJ et al (2005) Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab 90:3202-3208
48. Derex L, Giraud P, Hanss M et al (1998) Spontaneous intrac-erebral hemorrhage revealing Addison's disease. Cerebrovasc Dis 8:240-243
49. Asherson RA, Hughes GR (1989) Recurrent deep vein thrombosis and Addison's disease in "primary" antiphospholipid syndrome. J Rheumatol 16:378-380
50. Satta MA, Corsello SM, Della Casa S et al (2000) Adrenal insufficiency as the first clinical manifestation of the primary antiphospholipid antibody syndrome. Clin Endocrinol (Oxf) 52:123-126
51. Espinosa G, Cervera R, Font J, Asherson RA (2003) Adrenal involvement in the antiphospholipid syndrome. Lupus 12:569-572
52. Vance ML, Mauras N (1999) Growth hormone therapy in adults and children. N Engl J Med 341:1206-1216
53. Colao A, Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352:1455-1461
54. Sartorio A, Cattaneo M, Bucciarelli P et al (2000) Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 108:486-492
55. Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288
56. Wildbrett J, Hanefeld M, Fucker K et al (1997) Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 105:331-335
57. Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, Bengtsson BA (1997) Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf) 46:69-74
58. Johansson JO, Landin K, Johannsson G et al (1996) Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost 76:422-428
59. Ishizu A, Shimizu C, Tsuji T et al (2004) Peripheral pulmonary embolism related to a thrombus of the inferior vena cava triggering fatal adrenal crisis in Sheehan's syndrome. Endocrin J 51:387-388
60. Tanriverdi F, Gul A, Eryol NK et al (2005) Massive cardiac thrombosis in a patient with Sheehan's syndrome. Endocrin J 52:709-714
61. Wallaschofski H, Donné M, Eigenthaler M et al (2001) PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 86:5912-5919
62. Wallaschofski H, Kobsar A, Koksch M et al (2003) Prolactin receptor signaling during platelet activation. Horm Metab Res 35:228-235
63. von Kanel R, Dimsdale JE (2000) Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol 65:357-369
64. Vosburgh CH, Richards AN (1903) An experimental study of the sugar content and extra vascular coagulation of the blood after administration of adrenalin. Am J Physiol 9:35-51
65. Biggs R, MacFarlane RG, Philling J (1947) Observations on fibrinolysis. Experimental activity produced by exercise or adrenaline. Lancet 1:405
66. Ingram GIC (1961) Increase in antihemophilic globulin activity following infusion of adrenaline. J Physiol 156:217-224
67. Grant PJ (1990) Hormonal regulation of the acute haemostatic response to stress. Blood Coagul Fibrinolysis 1:299-306
68. Shulkin BL, Shapiro B, Sisson JC (1987) Pheochromocytoma, polycythemia, and venous thrombosis. Am J Med 83:773-776
69. Stevenson S, Ramani V, Nasim A (2005) Extra-adrenal pheochromocytoma: an unusual cause of deep vein thrombosis. J Vasc Surg 42:570-572
70. Stella P, Bignotti G, Zerbi S et al (2000) Concurrent pheochromocytoma, diabetes insipidus and cerebral venous thrombosis-a possible unique pathophysiological mechanism. Nephrol Dial Transplant 15:717-718
71. Hoppener MR, Kraaijenhagen RA, Hutten BA et al (2004) Beta-receptor blockade decreases elevated plasma levels of factor VIII:C in patients with deep vein thrombosis. J Thromb Haemost 2:1316-1320
72. Vaughan DE, Lazos SA, Tong K (1995) Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 95:995-1001
73. Brown NJ, Agirbasli MA, Williams GH et al (1998) Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans. Hypertension 32:965-971
74. Oikawa T, Freeman M, Lo W et al (1997) Modulation of plas-minogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51:164-172
75. Ganguly A (1998) Primary aldosteronism. N Engl J Med 339:1828-1834
76. Milliez P, Girerd X, Plouin PF et al (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243-1248
77. Rosendaal FR (1999) Venous thrombosis: a multicausal disease. Lancet 353:1167-1173